Susquehanna Fundamental Investments’s Protagonist Therapeutics PTGX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,524	Closed	-$634K	–	1665
2021 Q4	$634K	Buy	18,524 +5,509	+42%	+$174K	0.02%	829
2021 Q3	$231K	Sell	13,015 -21,605	-62%	-$921K	﹤0.01%	1492
2021 Q2	$1.55M	Sell	34,620 -13,000	-27%	-$429K	0.03%	686
2021 Q1	$1.23M	Buy	47,620 +6,319	+15%	+$160K	0.02%	807
2020 Q4	$833K	Sell	41,301 -99	-0.2%	-$2.13K	0.02%	924
2020 Q3	$809K	Buy	41,400 +21,400	+107%	+$402K	0.02%	720
2020 Q2	$353K	Buy	+20,000	New	+$251K	0.02%	701

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Susquehanna Fundamental Investments's PTGX Position: Q1 2022 in Review

Susquehanna Fundamental Investments sold out of Protagonist Therapeutics (PTGX) in Q1 2022, closing a stake of 18,524 shares — an estimated $634K sold.

Susquehanna Fundamental Investments first reported a position in PTGX in Q2 2020 and held it in 7 quarters. The position peaked at $1.55M in Q2 2021. 140 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

Susquehanna Fundamental Investments reported no remaining Protagonist Therapeutics position as of Q1 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 18,524 Protagonist Therapeutics shares in Q1 2022, an estimated $634K.
Susquehanna Fundamental Investments first reported a position in Protagonist Therapeutics in Q2 2020 and held it in 7 quarters.
Susquehanna Fundamental Investments's Protagonist Therapeutics position peaked at $1.55M in Q2 2021.
140 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.